Protagonist Therapeutics, Inc. (PTGX) SEC Filings & Earnings Calls

Dependence on Takeda for rusfertide commercialization

“We are dependent on Takeda for the commercialization of rusfertide. Failure by Takeda to commercialize rusfertide could result in a material adverse effect on our business and operating results.” · word for word

Macroeconomic and tariff uncertainty

“Unstable market and macroeconomic conditions, including geopolitical instability and tariffs or trade policy, may have serious adverse consequences on our business, financial condition and stock price.” · word for word

Regulatory risk for rusfertide NDA

“rusfertide NDA under Priority Review with PDUFA date in August 2026; FDA decision could significantly impact stock”

Commercial execution risk for ICOTYDE

“ICOTYDE is in first full quarter of commercial sales; early adoption strong but long-term trajectory uncertain”

Increased share dilution from new equity plan may pressure EPS and shareholder value.

“Approval of 2026 Equity Incentive Plan with additional shares.”

Clinical development risk

“We may never succeed in achieving marketing approval for our current or future product candidates regardless of our costs and efforts.” · word for word

Revenue concentration on milestones

“Our revenue is derived from licensing and collaboration agreements and is highly variable and dependent upon factors such as the timing of when regulatory and sales milestones are achieved” · word for word

R&D expenses increased 30% year-over-year, indicating continued investment in pipeline

“Research and development expense $46.7 million, compared to $35.9 million in Q1 2025”

Dependence on regulatory approvals for rusfertide (PDUFA August 2026) and future pipeline milestones

“Rusfertide NDA accepted with Priority Review, PDUFA goal date in August 2026”

Revenue concentration and variability from milestone payments

“License and collaboration revenue decreased by $388.4M due to lower milestone and collaboration revenue, which is highly variable.” · word for word

Regulatory approval uncertainty for rusfertide and ICOTYDE

“NDA submitted but FDA approval not guaranteed; regulatory decision for ICOTYDE anticipated in 2026.”

Revenue Concentration on Milestone Payments

“License and collaboration revenue decreased by $388.4 million from $434.4 million for the year ended December 31, 2024 to $46.0 million for the year ended December 31, 2025. The decrease in revenue was primarily attributable to lower milestone and collaboration revenue, which is highly variable and dependent upon factors such as the timing of when regulatory” · word for word

Clinical Trial Failure Risk

“We may never succeed in achieving marketing approval for our product candidates regardless of our costs and efforts. The probability of success of our product candidates may be affected by numerous factors, including pre-clinical data, clinical data, competition, manufacturing capability, our cost of goods to be sold, our ability to receive, and the timing o” · word for word

Operating Losses

“(Loss) income from operations $(158,127) thousand”

Clinical and regulatory risk for pipeline assets

“Dependence on FDA/EMA approvals for icotrokinra and rusfertide; no revenue yet”

Revenue dependency on milestone payments

“Revenue in 2025 is expected to reduce significantly, which will also impact our net income.” · word for word

No approved products; clinical and regulatory risk

“We may never succeed in achieving marketing approval for our product candidates regardless of our costs and efforts.” · word for word

Cash burn from increased R&D

“We expect to continue to incur significant research and development expenses, and other expenses related to our ongoing operations.” · word for word